Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

A man in Saudi Arabia diagnosed with shingles suffered a rare and potentially life-threatening infection that ate away the ...

Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...

Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...